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Summary Local extension prevents curative resection in more than two-thirds of gastric cancer patients. Unfortunately, resectability is one of
the main prognostic factors in these patients, and survival is longer when tumours are completely removed. Preoperative chemotherapy is an
attractive concept for obtaining curative resection. Thirty-two locally advanced unresectable gastric cancer patients were enrolled in five
Italian Group for the Study of Digestive Tract Cancer (GISCAD) centres. For 16 patients, surgical unresectability was based on computerized
tomography scan evaluation of tumour size (four patients) and invasion of adjacent structures (12 patients), whereas in another 16 patients
locally advanced disease was confirmed by laparotomy. They received weekly administration of cisplatin 40 mg m-2. 5-fluorouracil
500 mg in-2, epidoxorbicin 35 mg m-2, 6S-stereoisomer of leucovorin 250 mg rT2 and glutathione 1.5 g m-2. From the day after to the day
before each chemotherapy administration, filgrastim was administered by subcutaneous injection at a dose of 5 lig kg-'. One cycle of therapy
consisted of eight weekty treatments. Fifteen of 32 patients (470o) responded to chemotherapy, whereas 13 (410%) had stable disease and
four (12°h) progressed on therapy. Of the 15 responding patients, 13 were completely resected after chemotherapy and two of them had a
complete pathological response. Two clinically responding patients were found unresectable at operation because of perntoneal seeding. At a
median follow-up from the start of treatment of 24 months (range 11-39 months), 10 of 13 resected patients are alive and eight are relapse
free. Three patients died after 11, 12. and 14 months respectively. Toxicity was acceptable: side-effects consisted mainly of grade 11 National
Cancer Institute common toxicity criteria (NCICTC) leucopenia and thrombocytopenia in ten patients. Neither treatment-related death nor
surgical complications in patients undergoing surgery were observed. This weekly intensive regimen enabled resection in half of previously
inoperable tumours with a moderate toxicity. It can be offered to patients with locally advanced unresectable gastric cancer to obtain curative
resection.
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Althourh gastric cancer is declinin2 in incidence. it remains a
significant cause of mortality from malignant diseases (Parkin et
al. 1988). At presentation. locallx advanced disease is common
and. in more than tuxo-thirds of cases. local extension prevents
curatixe resection. Unfortunatelv. resectabilitx is one of the main
prognostic factors in patients with gastric carcinoma and surxix-al
is longer w-hen tumours are completely removed (Roder et al.
1993). The use of neoadjuvant chemotherapy is an attractive
concept to increase curative resection. A number of trials have
tested neoadjux ant chemotherapy. demonstrating that preoperative
chemotherapy is feasible and can increase the resection rate
(Wilke et al. 1990: Plukker et al. 1991. Ajani et al. 1993: RouDtier
et al. 1994: Kelsen et al. 1996: Melcher et al. 1996). Few studies.
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howex er. assessed preoperative chemotherapy in patients with
unresectable gastric cancer at initial surgerx. This approach
allow-ed radical surgery in about 40%' of patients with tumours
previously unresectable (Wilke et al. 1990: Plukker et al. 1991).
In a pilot clinical trial. a wxeekly lowx-dose treatment of 5-
fluorouracil (5-Fl.). epidoxorubicin (epiADR). cisplatin (CDDP).
6S-leucovorin. clutathione and bone marrow support w-ith the
haematopoietic growth factor filgrastim determined objectixe
responses in 25 of 34 advanced gastric cancer patients Nx-ith a mild
toxicitx (Cascinu et al. 1993). These results were confirmed in a
large confirmatory phase II clinical trial carried out in a multi-
institutional setting by- the Italian Group for the Study ofDigestive
Tract Cancer (GISCAD). In this studv. 5 (45%, ) of I1 patients wxith
only locally adxvanced unresectable gastric tumour [determined by
computerized tomography (CT) scan and endoscopy or by lapa-
rotomry] responded to chemotherapy andwxere completely resected
(Cascinu et al. 1997).
On the basis of these results. a study was carried out in five
GISCAD centres to assess this weeklx intensixe chemotherapy as
primary treatment in locally adxanced unresectable gastric cancer.
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PATIENTS AND METHODS
Patient selection
Patients with histologically -erified adxanced oastric carcinoma
were eliaible for the study. Patients thought to haxe potentially
curable disease by resection of the primary were not eligible.
A diagnosis of locally adxanced unresectable disease could be
based on CT scan exaluation of tumour size (> 7 cm) and/or
inxasion of adjacent structures (pancreas. aorta. omentum and
oesophaous or hepatic extension) or it could be confinned by
laparotomy as part of a failed attempt at radical primary surgery.
Other eliaibilitx criteria included performance status Eastern
Cooperatix-e Oncology Group grade 0 to 2. age < 70 years. and
normal lix er (serum bilirubin < 1.5 mc dl-'.) renal (serum creatinine
< 1.5mc dl-'). and bone marrowx (leucocyte count >4000i1-K.
platelet count > 100 000p1-1) functions. Because epi-ADR was
included in the treatment plan. patients had to haxe a New York
Heart Association class of < 2: if there was a history of cardiac
disease. a cardiac-gated pool scan w-ith an ejection fraction of
> 45%xcwas required. Informed consent was obtained from all
participants after the nature of the study had been fully explained
and the protocol A-as approxed by the institutional review board.
Chemotherapy
The chemotherapeutic regimen consisted of a once a week admin-
istration of CDDP 40 mc m- as a 30-min infusion in 250 ml of
normal saline solution. 5-FU 500 mu m- as a 15-min infusion in
100 ml of normal saline solution. epi-ADR 35 mg m- by intra-
venous bolus. 6S-Stereoisomer of leucoxonin was administered at
a dose of250 mg m- diluted in 250 ml ofnormal saline solution in
a 4-h infusion concurrent with hy dration.
Glutathione was gixen at a dose of 1.5 m- in 100 ml of
normal saline ox er 15 min immediately before each CDDP admin-
istration to prevent CDDP-associated neurotoxicity as indicated by
our previous experience (Cascinu et al. 1995). Standard intra-
xvenous hydration was used: 2 h before initiation of the CDDP
infusion. patients were hydrated with 1500 ml of 0.9% sodium
chloride to which 20 mequiv. of potassium chloride and 15 mequiv.
of magnesium sulphate w ere added. Post-hydration as continued
for 2 h xwith 1000 ml of normal saline solution. As antiemetic
regimen. all patients receixed dexamethasone 20 mg in 50 ml of
saline gixen as an intravenous infusion ox er 15 mmn. 45 min before
CDDP. and ondansetron 8 mg made up to 50 ml of saline as an
intraxenous infusion over 15 mmn.
From the day after to the day before each chemotherapy admin-
istration. filgrastim Wxas administered by subcutaneous injection at
a dose of5 igr ko-'. One cycle oftherapy consisted ofeight w-eekly
treatments. Full doses of anti-cancer drugs were grixen ifthe leuco-
cvte count w as 4000 gi-I and if the platelet count A-as greater than
100 000 g1-1: when the leucocvte and platelet counts were less
than this. we delayed the treatment by a week or until a complete
recox ery occurred. If rade 2 and 3 mucositis or diarrhoea
occurred. treatment w as delay ed by a wxeek or until normalization.
For grade 4 toxicities. patients wxere remox-ed from the study.
Evaluation of response and toxicity
Ex aluation of response w-as performed after 8 weeks of therapy.
whereas toxicity A-as exaluated weekly. To assess primary
tumour. patients were required to haxe a CT scan and endoscopic
evaluation wxith biopsv if tumour xx-as visible. Partial response
PR) A-as defined as haxInc both CT scan exidence of PR and
endoscopy shoxx ing a > 50%c reduction in the -isible tumour or
complete disappearance of tumour but positix-e histology on
biopsy of the previously involved areas. Complete response (CR)
ofthe primary site was defined as a normal appearing stomach on
CT scan with a complete resolution of the endoscopically visible
tumour and a negatix e biopsy ofthe original site of tumour.
Patients proceeded to laparotomrn only if a radical excision v as
felt to be a possibility.
Toxicity from chemotherapy w-as recorded weekly on haemato-
logical and biochemical parameters and by regular patient inter-
View accordinc to National Cancer Institute common toxicitx
criteria (National Cancer Institute. 1990).
RESULTS
Inxestigators from fixve institutions enrolled 32 patients A-ith
locallv advanced unresectable rastric cancer from September 1993
to August 1996. The median follow-up from the start of treatment
was 24 months (range 10-39 months). For 16 patients. the diag-
nosis A-as based on CT scan evaluation of tumour size (four
patients) and invasion of adjacent structures (12 patients). In
another 16 patients locally advanced disease >-as confirmed by
laparotomy. The characteristics of these patients are detailed in
Table 1. All patients receix ed eight w-eekly treatments.
Tumour response
Fifteen of 32 patients (47%c) responded to chemotherapy. whereas
13 (41%e ) had stable disease and four ( 12c) progressed on therapy.
Ofthe 15 responding patients. 13 (41%7c) Aere completely resected
after chemotherapy. Two patients had a complete pathological
response. Two clinically responding, patients were found unre-
sectable at operation because ofperitoneal seedlings.
Table 1 Patient charactenstics
No. of patients
Age (years)
Median
Range
Sex(M/F)
Performance status (ECOG)
0
32
60
42-71
21/11
19
9
4
Sites of primary tumour
Gastro-oesophageal junction
Proximal stomach
Body
Distal stomach
Laparotomy
Yes
No
Histological type
(adenocarcinoma)
Well differentiated
Moderately differentiated
Poorly differentiated
6
3
17
6
16
16
7
19
6
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At a median follow-up from the start of treatment of 24 months
(range 10-39 months). 10 of 13 resected patients (31%-) are alive
and eight are relapse free. Three patients died after 11. 12 and 14
months. Median survival for the whole group of patients was 11
months: it was 14 months in resected patients and 7.5 months in
inoperable patients.
At study entry. 14 patients were symptomatic: abdominal pain
w-as present in eight patients and dysphagia in six patients. After
chemotherapy. symptoms disappeared in four patients and
improved in five patients (five obtaining an objective response and
four stable disease). Analgesics were discontinued in four patients
and reduced in five patients.
Toxicity
Toxicity was acceptable. No treatment-related death was observed.
Specific treatment toxicities consisted of grade II leucopenia and
thrombocytopenia that determined a delay in ten patients for a
week and in seven for 2 weeks. Non-haematological toxicities
were uncommon and mild (Table 2). No dose modifications were
required.
No surgical complications were recorded in the 15 patients who
underwent radical surgerv or laparotomv.
DISCUSSION
Preoperative chemotherapy seems to be a logical approach to
improving surgical resectabilitv. one ofthe main prognostic factors
in patients with gastric carcinoma. Our series examined the effects
of a short intensiv-e weekly combination chemotherapy in initially
unresectable tumours ofthe stomach. A major problem in this area
is accurately cateconrzing patients into resectable and unresectable
groups. Ideal initial assessment is by direct surgical vision. but to
subject everv patient to laparotomy would clearly contribute
siginificantly to treatment morbidity. A less invasive preoperative
staaing. although accurate. may be guaranteed by new techniques
such as endoluminal oesophageal ultrasonography. laparascopy
and laparoscopic ultrasound. Experiences with these different
approaches suggest interestinc sensitivity and specificity in the
assessment of the stage of primary tumour. identification of
hepatic metastases. regional nodal involvement or the determina-
tion of small-volume peritoneal disease (Lightdale. 1992: Rougier
et al. 1994: Wilke et al. 1994). Unfortunately. these procedures are
available in only a few centres. However. a reasonably accurate
definition of inoperabilitv can also be obtained with traditional
techniques. In fact. patients with some characteristics such as: a
bulky tumour (>7 cm) or clear signs by CT scan of infiltration of
pancreas. aorta. omentum and oesophagus or hepatic extension
should not undergo surgerv because it is extremely unlikelv that
thev can be completely resected as a CT scan has an accuracy of
80-90%c for the estimation of locoregional extension. and bulky-
tumours are associated with a high probability of inoperabilitv
(Sussman et al. 1988: Rougier et al. 1994). On the basis of these
considerations. in our study. 16 patients were defined as not
resectable after laparotomv. but only as a part of a failed attempt
at radical primarv surgery. and 16 patients were defined as not
resectable on the basis ofendoscopic and CT scan findings.
Accurate objective measure of tumour response to
chemotherapy carries the same difficulties as initial assessment. In
our patients. after eight weekly chemotherapeutic administrations.
tumour assessment was made by- a combination of CT scan and
Table 2 Treatment toxicity (NCICTC). Worst toxicity per patient
Grade 1 Grade 2 Grade 3 Grade 4
Leucopenia 11 10
Throfmbocytopenia 7 7
Anaemia 3 1
Mucositis 2 1 - -
Diarrhoea 2 - - -
Nausea/vomiting 4 2 - -
Neurotoxicity - - - -
endoscopy. Our response rate of 47'% (15/32 patients) compares
well with other regimens. Of these 15 responding patients. 13
(41%c) were completely resected. Six ofthem were initiallv consid-
ered unresectable after laparotomy and seven after the radiological
work-up.
These results seem to be superior to those obtained by Wilke et
al (1990) with the etoposide. adrv-anicin. cisplatin (EAP) regimen
and bv Plukker et al ( 1991 ) with a methotrexate/5-FLT combination.
in terms of tolerability or those obtained by Melcher et al (1996)
with epidoxorubicin. cisplatin. 5 fluorouracil (ECF) regimen. in
terms of efficacy. Wilke and Plukker reported 44%7 and 40% of
completely resected patients. respectively. but EAP-associated
toxicity has been impressive (Kelsen et al. 1992). and the high-
dose methotrexate/5-FU combination Generally requires hospital-
ization and can frequently cause severe side-effects (Plukker et al.
1991). On the other hand. in Melcher's (1996) study only one of
the ten unresectable patients achieved complete surgical resection
after chemotherapy. Furthermore. our regimen was able to present
the advantage ofa shorter period treatment (8 weeks) than EAP ( 12
weeks) or ECF (24 weeks). In reality, in the Melcher experience
ECF was used for four cvcles only (12 weeks) as opposed to
Marsden's eight cycles (24 weeks) (Findlay et al. 1994). This may
be responsible for the observed lower activity, as argued by the
authors themselves, suggcesting the need for a more prolonged
duration oftherapy to maximize response to this regimen.
Another favourable aspect ofourregimen is the mild and accept-
able toxicity. We did not observe any surgical complication in the
15 patients who underwent surgery or grade IH-IV NCICTC.
A point of interest arisingr from this w-ork is the reliefof abdom-
inal pain and dysphagia in about 60%c of patients complaining, of
these symptoms. Although caution is required in the interpretation
ofthese data because a formal assessment of symptom control was
not included in this studv. these results seem to support the use of
this recrimen as palliative measure also.
In addition, the median survival of resected patients ( 14
months). compared with that Generally reported for unresectable
patients (5-6 months). strengthens our belief that this treatment
approach should be offered to all patients with locally advanced
gastric cancer not amenable to complete surgical resection.
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